These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17547518)

  • 1. Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.
    Welch SA; Moore MJ
    Future Oncol; 2007 Jun; 3(3):247-54. PubMed ID: 17547518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Iyer R; Bharthuar A
    Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting HER1/EGFR in cancer therapy: experience with erlotinib.
    Giaccone G
    Future Oncol; 2005 Aug; 1(4):449-60. PubMed ID: 16556021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
    J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
    J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.
    Tzeng CW; Frolov A; Frolova N; Jhala NC; Howard JH; Vickers SM; Buchsbaum DJ; Heslin MJ; Arnoletti JP
    Ann Surg Oncol; 2007 Jul; 14(7):2150-8. PubMed ID: 17453292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA drug approval summary: erlotinib (Tarceva) tablets.
    Cohen MH; Johnson JR; Chen YF; Sridhara R; Pazdur R
    Oncologist; 2005 Aug; 10(7):461-6. PubMed ID: 16079312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does erlotinib restore chemosensitivity to chemotherapy in pancreatic cancer? A case series.
    Saif MW
    Anticancer Res; 2011 Mar; 31(3):1039-42. PubMed ID: 21498735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
    Chang BW; Saif MW
    JOP; 2009 May; 10(3):231-6. PubMed ID: 19454812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib OSI/Roche/Genentech.
    Kim TE; Murren JR
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1385-95. PubMed ID: 12498017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
    Gridelli C; Maione P; Bareschino MA; Schettino C; Sacco PC; Ambrosio R; Barbato V; Falanga M; Rossi A
    Anticancer Res; 2010 Apr; 30(4):1301-10. PubMed ID: 20530444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?
    Laurent-Puig P; Taieb J
    Curr Opin Oncol; 2008 Jul; 20(4):454-8. PubMed ID: 18525343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
    Langer CJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib.
    Steins M; Thomas M; Geissler M
    Recent Results Cancer Res; 2010; 184():21-31. PubMed ID: 20072828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.